New drug aims to curb relentless hunger in rare genetic disorder
NCT ID NCT07348601
First seen Jan 17, 2026 · Last updated May 17, 2026 · Updated 12 times
Summary
This early-stage trial tests an experimental drug called CSTI-500 in 12 people with Prader-Willi syndrome, a genetic condition that causes constant, extreme hunger. The study aims to see if the drug is safe and can reduce the urge to overeat. Participants aged 13 to 50 will receive increasing doses, with blood tests used to personalize their treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRADER-WILLI SYNDROME are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Vanderbilt University Medical Center
RECRUITINGNashville, Tennessee, 37232, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.